Max Planck, Alnylam Sue Whitehead, MIT, UMass for Breach of Contract in RNAi Patent Filings | GenomeWeb

This article was originally published on June 29.

The Max Planck Society, Max Plank Innovation, and Alnylam Pharmaceuticals are suing a trio of Massachusetts research institutions for allegedly breaching their contractual and fiduciary duties in prosecuting patents surrounding RNA interference technology.

The complaint, filed late last week in Suffolk County Superior Court in Boston, names as defendants the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology, and the University of Massachusetts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.